NYSE · EVMN
Healthcare · Biotechnology
$10.56
Down-$0.28 (-2.58%)
Updated Sep 11, 2026, 5:54 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
EVMN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning EVMN.
EVMN research
Company profile and research snapshot.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | RBC Capital | Outperform | — |
| Sep 9, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 26, 2026 | Needham | Buy | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
Generated Sep 10, 2026, 9:24 PM
Evommune shares fell 2.58% today following the company's announcement that its Phase 2b trial for EVO756 in atopic dermatitis failed to meet its primary endpoint. The biotech is pivoting its strategy by discontinuing the atopic dermatitis program while redirecting EVO756 development toward migraine prophylaxis, a move that has prompted multiple analyst price target reductions.
Bottom line: Evommune faces a critical inflection point following its atopic dermatitis trial failure, but the company's decision to pursue migraine prophylaxis and maintain analyst support suggests management retains credibility. Investors should monitor upcoming migraine efficacy data closely, as success in this indication could partially offset the setback, though the near-term stock sentiment remains challenged by reduced price targets and pipeline uncertainty.
Yahoo · Sep 9, 2026
Evommune stock dropped Wednesday after its experimental eczema treatment flopped in midstage testing. The bearish news followed another miss for the drug in treating hives.
Benzinga · Sep 9, 2026
Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $28 to $22.
Yahoo · Sep 9, 2026
On Tuesday, clinical-stage biotechnology company Evommune Inc. (NYSE:EVMN) announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic dermatitis. Phase 2b Clinical Trial Findings The study evaluated the efficacy and safety profile of oral EVO756, a Mas-related G-protein coupled receptor X2 antagonist. The trial enrolled 121 adult patients with moderate-to-severe atopic dermatitis over an active 12-week treatment period, with researchers mon
Benzinga · Sep 9, 2026
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $29 to $21.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EVMN.
